EPIDEMIOLOGICAL PROFILE OF YOUNG WOMEN DIAGNOSED WITH BREAST CANCER TREATED AT A MASTOLOGY SERVICE IN THE FEDERAL DISTRICT
DOI:
https://doi.org/10.56238/arev8n2-090Keywords:
Breast Cancer, Young Women, Public Health Policies, ScreeningAbstract
Breast cancer remains one of the main public health challenges in Brazil, especially given the controversies related to the age of initiation of mammographic screening. Although the guidelines of the Unified Health System (SUS) recommend population screening only from the age of 50, recent epidemiological evidence points to a significant incidence of the disease in younger women. In this context, the present study aimed to analyze the epidemiological, clinical, and diagnostic profile of women with breast cancer treated at a public mastology referral service in the Federal District, with an emphasis on the population under 50 years of age, contributing to the debate on the anticipation of screening to the age of 40. This is an observational, retrospective, cross-sectional, and descriptive study based on a review of medical records of patients treated at the mastology outpatient clinic of the Taguatinga Regional Hospital between January and December 2024. 171 cases of breast cancer were identified in women under 50 years of age, predominantly in the 40-49 age group. A high proportion of diagnoses at advanced stages, a high frequency of lymph node involvement, and a predominance of biologically aggressive tumor subtypes were observed, resulting in more invasive therapeutic approaches. The findings highlight a gap between the current screening policy and the observed epidemiological reality, reinforcing the need for a critical review of national guidelines and the implementation of organized early detection strategies starting at age 40.
Downloads
References
[1] INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). Estimativa 2023: incidência do Câncer no Brasil. Rio de Janeiro: INCA, 2022. Disponível em: <https://www.gov.br/inca/pt- br/assuntos/cancer/numeros/estimativa>. Acesso em: 28 jan. 2026.
[2] AMERICAN CANCER SOCIETY. Cancer Facts & Figures 2024. Atlanta: American Cancer Society, 2024. Disponível em: <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer- facts-figures.html>. Acesso em: 28 jan. 2026.
[3] BRASIL. Ministério da Saúde. Secretaria de Atenção à Saúde. Nota Técnica nº 626/2025- CGPADI/DAPES/SAS/MS. Assunto: Rastreamento do câncer de mama no Brasil. Brasília, DF: Ministério da Saúde, 2025.
[4] SOCIEDADE BRASILEIRA DE MASTOLOGIA (SBM). Recomendações da Sociedade Brasileira de Mastologia para o Rastreamento do Câncer de Mama. São Paulo: SBM, 2023. Disponível em: <https://sbmastologia.com.br/para-o-medico/ministerio-da-saude-amplia-acesso-a-mamografia-a-partir-dos- 40-anos/>. Acesso em: 28 jan. 2026.
[5] BRASIL. Lei nº 11.664, de 29 de abril de 2008. Dispõe sobre a efetivação de ações de saúde que assegurem a prevenção, a detecção, o tratamento e o seguimento dos cânceres do colo uterino e de mama, no âmbito do Sistema Único de Saúde (SUS). Diário Oficial da União, Brasília, DF, 30 abr. 2008.
[6] COLÉGIO BRASILEIRO DE RADIOLOGIA E DIAGNÓSTICO POR IMAGEM (CBR). Recomendações do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem para o Rastreamento do Câncer de Mama. São Paulo: CBR, 2023. Disponível em: <https://cbr.org.br/wp-content/uploads/2023/09/Recomendacoes-do- Colegio.pdf>. Acesso em: 28 jan. 2026.
[7] DUFFY, S. W. et al. Annual mammographic screening to reduce breast cancer mortality in women from age 40: a cluster-randomized trial. The Lancet Oncology, v. 21, n. 11, p. 1453-1461, 2020. DOI: https://doi.org/10.1016/S1470-2045(20)30398-3
[8] SUNG, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, v. 71, n. 3, p. 209-249, 2021. DOI: https://doi.org/10.3322/caac.21660
[9] INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). Controle do câncer de mama no Brasil: dados e números 2024. Rio de Janeiro: INCA, 2024. Disponível em:<https://ninho.inca.gov.br/jspui/bitstream/123456789/17002/1/Controle%20do%20c%C3%A2ncer%20de%2 0mamano%20Brasil%20-%20dados%20e%20n%C3%BAmeros%202024.pdf>. Acesso em: 28 jan. 2026.
[10] CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). Breast Cancer Among Women Younger Than 45. Atlanta: CDC, 2025. Disponível em: <https://www.cdc.gov/united-states-cancer- statistics/publications/breast-cancer-among-young-women.html>. Acesso em: 28 jan. 2026.
[11] PEROU, C. M. et al. Molecular portraits of human breast tumours. Nature, v. 406, n. 6797, p. 747-752, 2000. DOI: https://doi.org/10.1038/35021093
[12] DOLLE, J. M. et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiology, Biomarkers & Prevention, v. 18, n. 4, p. 1157-1166, 2009. DOI: https://doi.org/10.1158/1055-9965.EPI-08-1005
[13] AZIM, H. A. Jr.; PARTRIDGE, A. H. Biology of breast cancer in young women. Breast Cancer Research, v. 16, n. 4, p. 427, 2014. DOI: https://doi.org/10.1186/s13058-014-0427-5
[14] BROEDERS, M. et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. Journal of Medical Screening, v. 19, n. 1_suppl, p. 14-25, 2012. DOI: https://doi.org/10.1258/jms.2012.012078
[15] US PREVENTIVE SERVICES TASK FORCE (USPSTF). Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, v. 331, n. 22, p. 1918-1930, 2024. Disponível em: <https://jamanetwork.com/journals/jama/fullarticle/2818283>. Acesso em: 28 jan. 2026. DOI: https://doi.org/10.1001/jama.2024.5534
[16] ANDERS, C. K.; JOHNSON, R.; LEREBOURS, F.; CAREY, L. A. The role of race in the clinical behavior of triple-negative breast cancer. Seminars in Oncology, v. 38, n. 2, p. 278-287, 2011.
[17] GRIMM, L. J. et al. Benefits and risks of mammography screening in women ages 40 to 49 years. Journal of Primary Care & Community Health, v. 13, 2022. DOI: https://doi.org/10.1177/21501327211058322
[18] THIAGO, L. S. et al. Diretrizes para detecção precoce do câncer de mama no Brasil. II - Novas recomendações nacionais, principais evidências e controvérsias. Cadernos de Saúde Pública, v. 34, n. 6, e00074817, 2018. DOI: https://doi.org/10.1590/0102-311x00074817
[19] BREAST CANCER RESEARCH FOUNDATION (BCRF). Facts About Breast Cancer in Young Women. New York: BCRF, [s.d.]. Disponível em: <https://www.bcrf.org/about-breast-cancer/breast-cancer-young- women/>. Acesso em: 28 jan. 2026.
[20] FEMAMA. Entenda o que é o câncer de mama triplo-negativo. Porto Alegre: FEMAMA, 2021. Disponível em: <https://femama.org.br/site/noticias-recentes/entenda-o-que-e-o-cancer-de-mama-triplo-negativo/>. Acesso em: 28 jan. 2026.